Numa-Kinjoh Natsuko, Komaru Keiichi, Ishida Yoko, Sohda Miwa, Oda Kimimitsu
Division of Oral Biochemistry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Kitasato Junior College of Health and Hygienic Sciences, Minami-Uonuma, Japan.
Mol Genet Metab. 2015 Aug;115(4):180-5. doi: 10.1016/j.ymgme.2015.05.006. Epub 2015 May 12.
Hypophosphatasia (HPP) is a genetic disease characterized by defective calcification of hard tissues such as bone and teeth accompanying deficiency of serum alkaline phosphatase (ALP) activity. Its development results from various mutations in the ALPL gene encoding tissue-nonspecific ALP (TNSALP). HPP is known to be transmitted in an autosomal recessive or autosomal dominant manner. A point mutation (c.323C>T) in the ALPL gene leading to a proline to leucine substitution at position 108 of TNSALP was first reported in a patient diagnosed with odonto-HPP (M Herasse et al., J Med Genet 2003;40:605-609), although the effects of this mutation on the TNSALP molecule have not been elucidated. To understand the molecular basis of this dominantly transmitted HPP, we first characterized TNSALP (P108L) by expressing it in COS-1 cells transiently. In contrast to wild-type TNSALP (WT), TNSALP (P108L) showed virtually no ALP activity. When coexpressed with TNSALP (WT), TNSALP (P108L) significantly inhibited the enzyme activity of TNSALP (WT), confirming that this mutant TNSALP exerts a dominant negative effect on TNSALP (WT). Using immunofluorescence and digestion with phosphatidylinositol-specific phospholipase C, we demonstrated that TNSALP (P108L) was anchored to the cell surface via glycosylphosphatidylinositol-like TNSALP (WT) in a Tet-On CHO cell expression system. Consistent with this, TNSALP (P108L) acquired endo-β-N-acetylglucosaminidase H resistance and sialic acids, as evidenced by glycosidase treatments. Importantly, TNSALP (WT) largely formed a functional dimeric structure, while TNSALP (P108L) was found to be present as a monomer in the cell. This indicates that the molecular structure of TNSALP is affected by a missense mutation at position 108, which is in contact with the active site, such that it no longer assembles into the functional dimeric form. Collectively, these results may explain why TNSALP (P108L) loses its ALP activity, even though it is able to gain access to the cell surface.
低磷酸酯酶症(HPP)是一种遗传性疾病,其特征是骨骼和牙齿等硬组织钙化缺陷,同时伴有血清碱性磷酸酶(ALP)活性缺乏。它的发生是由于编码组织非特异性ALP(TNSALP)的ALPL基因发生了各种突变。已知HPP以常染色体隐性或常染色体显性方式遗传。在一名被诊断为牙本质型HPP的患者中首次报道了ALPL基因中的一个点突变(c.323C>T),该突变导致TNSALP第108位的脯氨酸被亮氨酸取代(M Herasse等人,《医学遗传学杂志》2003年;40:605 - 609),尽管该突变对TNSALP分子的影响尚未阐明。为了了解这种显性遗传的HPP的分子基础,我们首先通过在COS - 1细胞中瞬时表达来对TNSALP(P108L)进行表征。与野生型TNSALP(WT)相比,TNSALP(P108L)几乎没有ALP活性。当与TNSALP(WT)共表达时,TNSALP(P108L)显著抑制了TNSALP(WT)的酶活性,证实了这种突变型TNSALP对TNSALP(WT)发挥了显性负效应。通过免疫荧光和用磷脂酰肌醇特异性磷脂酶C消化,我们证明了在Tet - On CHO细胞表达系统中,TNSALP(P108L)通过糖基磷脂酰肌醇样结构与TNSALP(WT)一起锚定在细胞表面。与此一致的是,糖苷酶处理证明TNSALP(P108L)获得了对内切β - N - 乙酰葡糖胺糖苷酶H的抗性和唾液酸。重要的是,TNSALP(WT)主要形成功能性二聚体结构,而TNSALP(P108L)在细胞中以单体形式存在。这表明TNSALP的分子结构受到与活性位点接触的第108位错义突变的影响,以至于它不再组装成功能性二聚体形式。总的来说,这些结果可能解释了为什么TNSALP(P108L)即使能够到达细胞表面也会失去其ALP活性。